Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers
NCT06923826Phase 2Recruiting
- Sponsor
- National University Hospital
- Start
- Apr 2025
- Primary completion
- Apr 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sacituzumab govitecan in salivary gland cancer (SGC) and Differentiated Thyroid Cancer (DTC) (2 arms), sponsored by National University Hospital. Primary endpoint: Objective Response Rate up to 3 years. Started Apr 2025; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
salivary gland cancer (SGC)Differentiated Thyroid Cancer (DTC)
Beyond the preview
Go deeper on NCT06923826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06923826.